Geron Corporation

Geron Corporation (NASDAQ: GERN) is a commercial-stage biopharmaceutical company headquartered in Foster City, California, focused on changing the course of blood cancers. Its first-in-class telomerase inhibitor RYTELO (imetelstat) is approved in the United States and the European Union for adults with transfusion-dependent anemia due to lower-risk myelodysplastic syndromes (LR-MDS). On August 5, 2026, Geron reported Q2 2026 net revenue of $57.5 million, up 17% year over year and 11% sequentially, on growing Rytelo demand — a beat that lifted the stock +21.64%.